News [Publication Type]

Endpoints News Topics at 2026 JPM Healthcare Conference: CEOs, Investors, China, and Beyond

1 month ago talkbio0Tagged AI healthcare, Biopharma, CEOs, Endpoints, investors, JPM Healthcare Conference, News [Publication Type], Private Equity

JPM Healthcare Conference; Endpoints News; CEOs; investors; AI healthcare; biopharma; private equity

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

1 month ago talkbio0Tagged 2025, Biopharma, Endpoints, Kyle LaHucik, Losers, movers, News [Publication Type], Pharma, Post-Hoc Live, Review [Publication Type], winners

Endpoints News; winners and losers; 2025; biopharma; Post-Hoc Live; Kyle LaHucik; year in review; biotech; pharma; stock movers

Recent news on Biopharma Sentiment Index (BPSI)

2 months ago talkbio0Tagged Attitude, Biopharma, Biopharma Sentiment Index, BPSI, drug development sentiment, Endpoints, investing, News [Publication Type], Pharma Industry, Sentiment

Biopharma Sentiment Index; BPSI; Endpoints News; biopharma sentiment survey; drug development sentiment; biotech investing sentiment; pharma industry outlook

Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery

2 months ago talkbio0Tagged cardiometabolic, Deal Value, eli lilly, LEAD platform, Metabolic Diseases, News [Publication Type], Pharma, RNAi medicines, SanegeneBio, South Korean biotech, strategic partnership

Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

3 months ago talkbio0Tagged AnaptysBio, CAR-T therapy, Clinical Failure, Clinical Trials, Discontinuation (procedure), Lyell Immunopharma, News [Publication Type], Phase 2 trial, Rheumatoid Arthritis, Rosnilimab, Ulcerative Colitis

AnaptysBio; rosnilimab; ulcerative colitis; Phase 2 trial; clinical failure; trial discontinuation; Lyell Immunopharma; CAR-T therapy; licensing deal; biotech news; rheumatoid arthritis